Clinical Trial Update: Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial assessing safety and efficacy of FAP iCDC in patients with end-stage dilated cardiomyopathy and heart failure; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Heart Failure

Drugs mentioned

• FAP iCDC

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Dilated Cardiomyopathy (DCM), Heart Failure | Phase 1 | Status: COMPLETED